Brain Tumor Radiogenomic Classification of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Malignant Gliomas-Based Transfer Learning

• Published in: Cancer Control Vol. 30; p. 10732748231169149
• Main Authors: Sakly, Houneida, Said, Mourad, Seekins, Jayne, Guetari, Ramzi, Kraiem, Naoufel, Marzougui, Mehrez
• Format: Book Review Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-04-2023; Sage Publications Ltd
• Subjects: Artificial intelligence; Big Data; Brain cancer; Brain tumors; Classification; Computational neuroscience; Diagnosis; DNA methylation; DNA methyltransferase; Electronic health records; Electronic medical records; Glioblastoma; Glioma; Health care; Magnetic resonance imaging; Medical prognosis; Methylguanine; Neuroimaging; Nucleotide sequence; O6-methylguanine-DNA methyltransferase; Patients; Precision medicine; Prognosis; Radiomics; Review; Transfer learning; Tumors; Transfer learning; radiogenomic; O6 -methylguanine-DNA methyltransferase promoter methylation; brain tumor; big data; classification; artificial intelligence
• ISSN: 1073-2748; 1526-2359
• DOI: 10.1177/10732748231169149

Artificial Intelligence (AI) is the subject of a challenge and attention in the field of oncology and raises many promises for preventive diagnosis, but also fears, some of which are based on highly speculative visions for the classification and detection of tumors. A brain tumor that is malignant is a life-threatening disorder. Glioblastoma is the most prevalent kind of adult brain cancer and the 1 with the poorest prognosis, with a median survival time of less than a year. The presence of O6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation, a particular genetic sequence seen in tumors, has been proven to be a positive prognostic indicator and a significant predictor of recurrence.
This strong revival of interest in AI is modeled in particular to major technological advances which have significantly increased the performance of the predicted model for medical decision support. Establishing reliable forecasts remains a significant challenge for electronic health records (EHRs). By enhancing clinical practice, precision medicine promises to improve healthcare delivery. The goal is to produce improved prognosis, diagnosis, and therapy through evidence-based sub stratification of patients, transforming established clinical pathways to optimize care for each patient’s individual requirements. The abundance of today’s healthcare data, dubbed “big data,” provides great resources for new knowledge discovery, potentially advancing precision treatment. The latter necessitates multidisciplinary initiatives that will use the knowledge, skills, and medical data of newly established organizations with diverse backgrounds and expertise.
The aim of this paper is to use magnetic resonance imaging (MRI) images to train and evaluate your model to detect the presence of MGMT promoter methylation in this competition to predict the genetic subtype of glioblastoma based transfer learning. Our objective is to emphasize the basic problems in the developing disciplines of radiomics and radiogenomics, as well as to illustrate the computational challenges from the perspective of big data analytics.